Lixisenatide

Known as: lixisénatide, L-histidylglycyl-L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-leucyl-L-seryl-L-lysyl-L-glutaminyl-L-methionyl-L-α-glutamyl-L-α-glutamyl-L-α-glutamyl-L-alanyl-L-valyl-L-arginyl-L-leucyl-L-phenylalanyl-L-isoleucyl-L-α-glutamyl-L-tryptophyl-L-leucyl-L-lysyl-L-asparaginylglycylglycyl-L-prolyl-L-seryl-L-serylglycyl-L-alanyl-L-prolyl-L-prolyl-L-seryl-L-lysyl-L-lysyl-L-lysyl-L-lysyl-L-lysyl-L-lysinamide, DesPro38Exendin-4(1-39)-Lys6-NH2 
 

Topic mentions per year

Topic mentions per year

2009-2017
05020092017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
BACKGROUND Cardiovascular morbidity and mortality are higher among patients with type 2 diabetes, particularly those with… (More)
  • table 1
  • table 1
  • figure 1
  • figure 2
  • table 3
Is this relevant?
2015
2015
BACKGROUND Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus… (More)
Is this relevant?
2013
2013
OBJECTIVES To determine the effects of lixisenatide, a new once-daily (QD) glucagon-like peptide-1 receptor agonist, on… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2013
Highly Cited
2013
OBJECTIVE When oral therapy for type 2 diabetes is ineffective, adding basal insulin improves glycemic control. However, when… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
Is this relevant?
Highly Cited
2013
Highly Cited
2013
OBJECTIVE To examine the efficacy and safety of adding the once-daily glucagon-like peptide-1 receptor agonist (GLP-1RA… (More)
  • figure 3
  • figure 1
  • table 2
  • figure 2
Is this relevant?
2013
2013
AIMS To compare the efficacy and safety of once-daily prandial lixisenatide with placebo in type 2 diabetes mellitus (T2DM… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
AIMS To assess the efficacy and safety of once-daily lixisenatide versus placebo in Asian patients with type 2 diabetes… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
OBJECTIVE To assess efficacy and safety of lixisenatide monotherapy in type 2 diabetes. RESEARCH DESIGN AND METHODS Randomized… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Type 2 diabetes is a risk factor for Alzheimer's disease (AD), most likely linked to an impairment of insulin signalling in the… (More)
  • figure 1
  • figure 2
Is this relevant?
2010
2010
AIMS To evaluate the dose-response relationship of lixisenatide (AVE0010), a glucagon-like peptide-1 (GLP-1) receptor agonist, in… (More)
  • figure 1
  • figure 2
  • table 3
Is this relevant?